⚠️ GLP-1 Pancreatitis Risk Monitoring Simulator

Baseline Patient Risk Profile

Three factors raise baseline pancreatitis risk before any drug is started.

• 3: Risk factors screened (history, gallstones, triglycerides)
• ~15%: Gallstone prevalence (T2D) (higher in obesity)
• ≥500 mg/dL: Triglyceride risk cutoff (severe hypertriglyceridemia)
• ~20–30%: Prior pancreatitis recurrence (general population estimate)

History of pancreatitis

Prior acute or chronic pancreatitis raises baseline recurrence risk.

Gallstone disease

Gallstones are the leading cause of acute pancreatitis overall.

Hypertriglyceridemia

Very high triglycerides independently trigger pancreatic inflammation.

GLP-1 Therapy Initiated

Drug-associated risk combines with existing baseline risk factors.

• ~0.2–0.3%: Reported incidence (across GLP-1 trial pools)
• Small: Absolute risk increase (vs. placebo in meta-analyses)
• Additive: Risk-factor multiplier (each factor raises baseline)
• Yes: Monitoring recommended (for risk-positive patients)

Drug-associated signal

Large trials show a small, inconsistent pancreatitis signal.

Combined risk model

Baseline factors plus drug exposure define total risk.

Patient selection

Risk-positive patients warrant closer clinical follow-up.

Warning Symptoms to Monitor

Persistent severe abdominal pain radiating to the back is the key sign.

• Epigastric pain: Hallmark symptom (radiates to back)
• Nausea / vomiting: Associated symptoms (common accompaniment)
• Sudden, persistent: Onset pattern (not intermittent cramping)
• >48 hours: Duration flag (warrants urgent evaluation)

Pain character

Severe, steady epigastric pain radiating posteriorly is classic.

Accompanying signs

Nausea, vomiting, and tenderness often occur together.

Patient education

Patients are told to report symptoms immediately, not wait.

Decision Point — Test and Hold

Symptom presence triggers lipase/amylase testing and possible drug hold.

• >3× ULN: Lipase threshold (supports diagnosis)
• >3× ULN: Amylase threshold (secondary marker)
• CT / ultrasound: Imaging option (confirms diagnosis, rules out stones)
• Hold therapy: Drug action (pending workup results)

Lab testing

Lipase and amylase confirm or rule out pancreatic inflammation.

Drug hold decision

Therapy is paused while results and symptoms are evaluated.

Escalation path

Confirmed cases move to imaging and specialist referral.

Outcome — Rare Event, Managed Early

Most patients never develop pancreatitis; early action limits severity.

• Low: Overall absolute risk (rare across GLP-1 users)
• Prevents progression: Early recognition benefit (to severe disease)
• Rare: Severe case rate (with prompt monitoring)
• Usually resolves: Post-discontinuation course (after drug hold)

Population-level risk

Absolute risk stays low even with risk factors present.

Value of monitoring

Symptom awareness catches cases before severe progression.

Ongoing care

Risk-positive patients continue closer routine surveillance.

Most patients on GLP-1 therapy never develop pancreatitis.